The estrogen receptor β-PI3K/Akt pathway mediates the cytoprotective effects of tocotrienol in a cellular Parkinson's disease model

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1303-1312

  Nakaso, Kazuhiro ^a   Tajima, Naoko ^a   Horikoshi, Yosuke ^a   Nakasone, Masato ^a   Hanaki, Takehiko ^a   Kamizaki, Kouki ^a   Matsura, Tatsuya ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Akt; Caveolin; Estrogen receptor; Parkinson's disease; PI3K; Vitamin E

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA TOCOTRIENOL; CAVEOLIN 1; CAVEOLIN 2; CYTOPROTECTIVE AGENT; ESTROGEN RECEPTOR BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; CAVEOLIN; SMALL INTERFERING RNA;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE FORMATION; NEUROBLASTOMA CELL LINE; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL VIABILITY ASSAY; DEGENERATIVE DISEASE; DISEASE MODEL; GENE SILENCING; NEUROBLASTOMA CELL; NEUROLOGIC DISEASE; NEUROPROTECTION;

AKT; CAVEOLIN; ESTROGEN RECEPTOR; PARKINSON'S DISEASE; PI3K; VITAMIN E;

ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CYTOPROTECTION; ESTROGEN RECEPTOR BETA; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; NEUROBLASTOMA; PARKINSON DISEASE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOCOTRIENOLS; TUMOR CELLS, CULTURED;

EID: 84903434831     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.008     Document Type: Article

References (50)

1. Kamal-Eldin A., Appelqvist L.A. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 1996, 31:671-701.
2. Sen C.K., Khanna S., Roy S. Tocotrienols: vitamin E beyond tocopherols. Life Sci. 2006, 27:2088-2098.
3. Elson C.E. Tropical oils: nutritional and scientific issues. Crit. Rev. Food Sci. Nutr. 1992, 31:79-102.
4. Sen C.K., Khanna S., Roy S. Tocotrienols in health and disease: the other half of the natural vitamin E family. Mol. Aspects Med. 2007, 28:692-728.
5. Packer L. Interactions among antioxidants in health and disease: vitamin E and its redox cycle. Proc. Soc. Exp. Biol. Med. 1992, 200:271-276.
6. Niki E., Yamamoto Y., Takahashi M., Komuro E., Miyama Y. Inhibition of oxidation of biomembranes by tocopherol. Ann. N. Y. Acad. Sci. 1989, 570:23-31.
7. Atkinson J., Epand R.F., Epand R.M. Tocopherols and tocotrienols in membranes: a critical review. Free Radic. Biol. Med. 2008, 44:739-764.
8. de Rijk M.C., Breteler M.M., den Breeijen J.H., Launer L.J., Grobbee D.E., van der Meche F.G., Hofman A. Dietary antioxidants and Parkinson disease. The Rotterdam study. Arch. Neurol. 1997, 54:762-765.
9. Zhang S.M., Hernan M.A., Chen H., Spiegelman D., Willett W.C., Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002, 59:1161-1169.
10. Fariss M.W., Zhang J.G. Vitamin E therapy in Parkinson's disease. Toxicology 2003, 189:129-146.
11. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Engl. J. Med. 1997, 336:1216-1222.
12. Ascherio A., Weisskopf M.G., O'Reilly E.J., Jacobs E.J., McCullough M.L., Calle E.E., Cudkowicz M., Thun M.J. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann. Neurol. 2005, 57:104-110.
13. Logroscino G., Marder K., Cote L., Tang M.X., Shea S., Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 1996, 39:89-94.
14. Parkinson study group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol. 1996, 39:37-45. Parkinson study group.
15. Farina N., Isaac M.G., Clark A.R., Rusted J., Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment (review). Cochrane Database Syst. Rev. 2012, 11. 10.1002/14651858.
16. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
17. Meissner W.G., Frasier M., Gasser T., Goetz C.G., Lozano A., Piccini P., Obeso J.A., Rascol O., Schapira A., Voon V., Weiner D.M., Tison F., Bezard E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393.
18. Stocchi F., Olanow C.W. Neuroprotection in Parkinson's disease: clinical trial. Ann. Neurol. 2003, 53:S87-S99.
19. Nakaso K., Nakamura C., Sato H., Imamura K., Takeshima T., Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun. 2006, 339:915-922.
20. Carbone M., Duty S., Rattray M. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. BMC Neurosci. 2012, 13. (doi: 1186/1471-2202-13-38).
21. Hickey P., Stacy M. Adenosine A2A antagonists in Parkinson's disease: what's next?. Curr. Neurol. Neurosci. Rep. 2012, 12:376-385.
22. Yacoubian T.A., Standaert D.G. Targets for neuroprotection in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:676-687.
23. Nakaso K., Ito S., Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci. Lett. 2008, 432:146-150.
24. Numakawa Y., Numakawa T., Matsumoto T., Yagasaki Y., Kumamaru E., Kunugi H., Taguchi T., Niki E. Vitamin E protected cultured cortical neurons from oxidative stress-induced cell death through the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. J. Neurochem. 2006, 97:1191-1202.
25. Takahama S., Hirose T., Ohno S. aPLC restricts the basolateral determinant PtdIns (3,4,5)P3 to the basal region. Biochem. Biophys. Res. Commun. 2008, 368:249-255.
26. Comitato R., Nesaretnam K., Leoni G., Ambra R., Canali R., Bolli A., Marino M., Virgili F. A novel mechanism of natural vitamin E tocotrienol activity: involvement of ERβ signal transduction. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E427-E437.
27. Liang K., Yang L., Yin C., Xiao Z., Zhang J., Liu Y., Huang J. Estrogen stimulates degradation of β-amyloid peptide by up-regulating neprilysin. J. Biol. Chem. 2010, 285:935-942.
28. Berthois Y., Katzenellenbogen J.A., Katzenellenbogen B.S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2496-2500.
29. Khanna S., Roy S., Park H.A., Sen C.K. Regulation of c-Src activity in glutamate-induced neurodegeneration. J. Biol. Chem. 2007, 282:23482-23490.
30. Liu X., Yamada N., Osaswa T. Assessing the neuroprotective effect of antioxidative food factors by application of lipid-derived dopamine modification adducts. Methods Mol. Biol. 2010, 594:263-273.
31. Fukui K., Sekiguchi H., Takatsu H., Koike T., Koike T., Urano S. Tocotrienol prevents AAPH-induced neurite degeneration in neuro2a cells. Redox Rep. 2013, 18:238-244.
32. Lopes F.M., Schroder R., da Fronta Jr M.L.C., Zanotto-Filho A., Muller C.B., Piers A.S., Meurer R.T., Colpo G.D., Gelain D.P., Kapczinski F., Moreira J.C.F., Fernandes M.da C., Klamt F. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson's disease studies. Brain Res. 2010, 1337:85-94.
33. Encinas M., Iglesias M., Llecha N., Comella J.X. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J. Neurochem. 1999, 73:1409-1421.
34. Atwal J.K., Massie B., Miller F.D., Kaplan D.R. The Trk B-Shc site signals neuronal survival and local axon growth via MEK and PI3-kinase. Neuron 2000, 27:265-277.
35. Mori Y., Higuchi M., Masuyama N., Gotoh H. Adenosine A2A receptor facilitates calcium-dependent protein secretion through the activation of protein kinase A and phosphatidylinositol-3 kinase in PC12 cells. Cell Struct. Funct. 2004, 29:101-110.
36. Nair V.D., Sealfon S.C. Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J. Biol. Chem. 2003, 278:47053-47061.
37. Mannella P., Brinton R.D. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action. J. Neurosci. 2006, 26:9439-9447.
38. Sun X., Yao H., Douglas R.M., Gu X.Q., Wang J., Haddad G.G. Insulin/PI3K signaling protects dentate neurons from oxygen-glucose deprivation in organotypic slice cultures. J. Neurochem. 2010, 112:377-388.
39. Powell E., Shanle E., Brinkman A., Li J., Keles S., Wisinski K.B., Huang W., Xu W. Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ. PLoS One 2013, 7:e30993.
40. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:5925-5930.
41. Marino M., Galluzzo P., Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics 2006, 7:497-508.
42. Ivanova T., Mendez P., Garcia-Segura L.M., Beyer C. Rapid stimulation of the PI3-kinase/Akt signaling pathway in developing midbrain neurones by oestrogen. J. Neuroendocrinol. 2002, 14:73-79.
43. Chamniansawat S., Chongthammakun S. Genomic and non-genomic actions of estrogen on synaptic plasticity in SH-SY5Y cells. Neurosci. Lett. 2010, 470:49-54.
44. Chambliss K.L., Yuhanna I.S., Anderson R.G., Mendelsohn M.E., Shaul P.W. ERβ has nongenomic action in caveolae. Mol. Endocrinol. 2002, 16:938-946.
45. Kim H.P., Lee J.Y., Jeong J.K., Bae S.W., Lee H.K., Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor α localized in caveolae. Biochem. Biophys. Res. Commun. 1999, 263:257-262.
46. Parton R.G. Caveolae and caveolins. Curr. Opin. Cell Biol. 1996, 8:542-548.
47. Marino M., Ascenzi P. Membrane association of estrogen receptor α and β influence 17β-estradiol-mediated cancer cell proliferation. Steroids 2008, 73:853-858.
48. Luoma J.I., Boulware M.L., Mermelstein P.G. Caveolin proteins and estrogen signaling in the brain. Mol. Cell. Endocrinol. 2008, 290:8-13.
49. Schapira A.H., Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths and misconceptions. JAMA 2004, 291:358-364.
50. Mizuno Y., Hattori N., Kubo S., Sato S., Nishioka K., Hatano T., Tomiyama H., Funayama M., Machida Y., Mochizuki H. Progress in the pathogenesis and genetics of Parkinson's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2008, 363:2215-2227.